Acorda Therapeutics (ACOR) Tops Q4 EPS by 108c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018
February 14, 2019 4:00 PM ESTINBRIJA (levodopa inhalation powder) approved December 21, 2018 first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinsons taking carbidopa/levodopa INBRIJA commercially available in 1Q19 AMPYRA® (dalfampridine) 4Q18 net revenue of $64.2 million 2018 year-end cash, cash equivalents and investments of $445 million
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ:... More
